We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Beats on Q2 Earnings & Revenues
Read MoreHide Full Article
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson, popularly known as BD, has a Zacks Rank #3 (Hold) but that could change following its second-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: BD posted fiscal second-quarter earnings of $2.65 which beat the Zacks Consensus Estimate of $2.61. Earnings also improved 7.8% at constant currency (cc).
Revenues: Revenues came in at $4.22 billion, beating the Zacks Consensus Estimate of $4.12 billion. Revenues also surged 42.2% from the year-ago quarter.
Becton, Dickinson and Company Price and EPS Surprise
Key Stats: BD Medical generated revenues of $1.18 billion, up 16.7% from year-ago quarter.
BD Life sciences generated revenues of $$498 million, up 6.5%, year over year.
Major Factors: The company has raised full fiscal year 2018 revenue and adjusted earnings per share guidance. The company has further reaffirmed that the acquisition of C.R. Bard is expected to be accretive to adjusted earnings per share on a high-single digit basis in fiscal year 2019.
The company has raised the revenue guidance to 5-5.5% growth, which is the high end of its previous guidance range. Full year adjusted earnings per share is expected to be between $10.90-11.0, reflecting a growth of 15-16.5% over fiscal 2017.
Stock Price: Shares of BD have risen roughly 25.2% in the past year, while the industry has gained 10.5% over the same time frame. However, following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Becton, Dickinson (BDX) Beats on Q2 Earnings & Revenues
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson, popularly known as BD, has a Zacks Rank #3 (Hold) but that could change following its second-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: BD posted fiscal second-quarter earnings of $2.65 which beat the Zacks Consensus Estimate of $2.61. Earnings also improved 7.8% at constant currency (cc).
Revenues: Revenues came in at $4.22 billion, beating the Zacks Consensus Estimate of $4.12 billion. Revenues also surged 42.2% from the year-ago quarter.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote
Key Stats: BD Medical generated revenues of $1.18 billion, up 16.7% from year-ago quarter.
BD Life sciences generated revenues of $$498 million, up 6.5%, year over year.
Major Factors: The company has raised full fiscal year 2018 revenue and adjusted earnings per share guidance. The company has further reaffirmed that the acquisition of C.R. Bard is expected to be accretive to adjusted earnings per share on a high-single digit basis in fiscal year 2019.
The company has raised the revenue guidance to 5-5.5% growth, which is the high end of its previous guidance range. Full year adjusted earnings per share is expected to be between $10.90-11.0, reflecting a growth of 15-16.5% over fiscal 2017.
Stock Price: Shares of BD have risen roughly 25.2% in the past year, while the industry has gained 10.5% over the same time frame. However, following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>